While the ERα status has been used to identify breast cancer patients who may respond to TAM, there are still 30%–50% of treated Erα-positive breast cancer cells that show resistance to TAM (Early Breast Cancer Trialists' Collaborative Group, 1998). This evidence concerns the gene ESR1 and breast cancer.